General description

Dactinomycin is an antineoplastic agent that inhibits DNA, RNA and protein synthesis. It is used in treatment protocols for many cancers including gestational trophoblastic neoplasia, rhabdomyosarcoma and Wilms tumour (nephroblastoma).

### INN
Dactinomycin

### ATC codes
L01DA01

### Medicine type
Chemical agent

### EML status history
- First added in 1984 (TRS 722) for Malignant trophoblastic neoplasms of placenta
- Added in 1984 (TRS 722) for Malignant neoplasms of kidney, except renal pelvis
- Added in 1984 (TRS 722) for Rhabdomyosarcoma primary site
- Added in 1984 (TRS 722) for Unspecified malignant neoplasms of ill-defined or unspecified sites
- Removed in 2015 (TRS 994) for Unspecified malignant neoplasms of ill-defined or unspecified sites
- Added in 2021 (TRS 1035) for Ewing sarcoma of bone and articular cartilage of unspecified sites

### Recommendations

#### Cytotoxic medicines

Parenteral > General injections > IV: 500 µg in vial powder for injection

**Indications**

- Malignant trophoblastic neoplasms of placenta
- Rhabdomyosarcoma primary site
- Malignant neoplasms of kidney, except renal pelvis
- Unspecified malignant neoplasms of ill-defined or unspecified sites
- Ewing sarcoma of bone and articular cartilage of unspecified sites